Cargando…
Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696690/ https://www.ncbi.nlm.nih.gov/pubmed/26692336 http://dx.doi.org/10.3201/eid2201.150736 |
_version_ | 1782407815613120512 |
---|---|
author | Cameron, Ross L. Kavanagh, Kimberley Pan, Jiafeng Love, John Cuschieri, Kate Robertson, Chris Ahmed, Syed Palmer, Timothy Pollock, Kevin G.J. |
author_facet | Cameron, Ross L. Kavanagh, Kimberley Pan, Jiafeng Love, John Cuschieri, Kate Robertson, Chris Ahmed, Syed Palmer, Timothy Pollock, Kevin G.J. |
author_sort | Cameron, Ross L. |
collection | PubMed |
description | In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each year during 2009–2013, the surveillance program conducted HPV testing on a proportion of liquid-based cytology samples from women undergoing their first cervical screening test for precancerous cervical disease. By linking vaccination, cervical screening, and HPV testing data, over the study period we found a decline in HPV types 16 and 18, significant decreases in HPV types 31, 33, and 45 (suggesting cross-protection), and a nonsignificant increase in HPV 51. In addition, among nonvaccinated women, HPV types 16 and 18 infections were significantly lower in 2013 than in 2009. Our results preliminarily indicate herd immunity and sustained effectiveness of the bivalent vaccine on virologic outcomes at the population level. |
format | Online Article Text |
id | pubmed-4696690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-46966902016-01-05 Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 Cameron, Ross L. Kavanagh, Kimberley Pan, Jiafeng Love, John Cuschieri, Kate Robertson, Chris Ahmed, Syed Palmer, Timothy Pollock, Kevin G.J. Emerg Infect Dis Research In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each year during 2009–2013, the surveillance program conducted HPV testing on a proportion of liquid-based cytology samples from women undergoing their first cervical screening test for precancerous cervical disease. By linking vaccination, cervical screening, and HPV testing data, over the study period we found a decline in HPV types 16 and 18, significant decreases in HPV types 31, 33, and 45 (suggesting cross-protection), and a nonsignificant increase in HPV 51. In addition, among nonvaccinated women, HPV types 16 and 18 infections were significantly lower in 2013 than in 2009. Our results preliminarily indicate herd immunity and sustained effectiveness of the bivalent vaccine on virologic outcomes at the population level. Centers for Disease Control and Prevention 2016-01 /pmc/articles/PMC4696690/ /pubmed/26692336 http://dx.doi.org/10.3201/eid2201.150736 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Cameron, Ross L. Kavanagh, Kimberley Pan, Jiafeng Love, John Cuschieri, Kate Robertson, Chris Ahmed, Syed Palmer, Timothy Pollock, Kevin G.J. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 |
title | Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 |
title_full | Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 |
title_fullStr | Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 |
title_full_unstemmed | Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 |
title_short | Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 |
title_sort | human papillomavirus prevalence and herd immunity after introduction of vaccination program, scotland, 2009–2013 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696690/ https://www.ncbi.nlm.nih.gov/pubmed/26692336 http://dx.doi.org/10.3201/eid2201.150736 |
work_keys_str_mv | AT cameronrossl humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013 AT kavanaghkimberley humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013 AT panjiafeng humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013 AT lovejohn humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013 AT cuschierikate humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013 AT robertsonchris humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013 AT ahmedsyed humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013 AT palmertimothy humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013 AT pollockkevingj humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013 |